13 analysts have expressed a variety of opinions on Edwards Lifesciences EW over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 3 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 5 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $96.23, a high estimate of $107.00, and a low estimate of $85.00. Surpassing the previous average price target of $90.75, the current average has increased by 6.04%.
Understanding Analyst Ratings: A Comprehensive Breakdown
The perception of Edwards Lifesciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $91.00 | $89.00 |
| David Roman | Goldman Sachs | Announces | Buy | $107.00 | - |
| Joanne Wuensch | Citigroup | Raises | Buy | $105.00 | $98.00 |
| Pito Chickering | Deutsche Bank | Raises | Buy | $103.00 | $86.00 |
| Matt Miksic | Barclays | Raises | Overweight | $101.00 | $100.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $85.00 | $86.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $99.00 | $94.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $89.00 | $92.00 |
| Rick Wise | Stifel | Raises | Hold | $85.00 | $83.00 |
| Adam Maeder | Piper Sandler | Raises | Neutral | $88.00 | $85.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $101.00 | $95.00 |
| Anthony Petrone | Mizuho | Raises | Buy | $105.00 | $95.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $92.00 | $86.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Edwards Lifesciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Edwards Lifesciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
To gain a panoramic view of Edwards Lifesciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Unveiling the Story Behind Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
A Deep Dive into Edwards Lifesciences's Financials
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Edwards Lifesciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.5% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Edwards Lifesciences's net margin is impressive, surpassing industry averages. With a net margin of 22.02%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Edwards Lifesciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.11% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Edwards Lifesciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.68% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
